Extracellular Matrix Protects Pancreatic β-Cells Against Apoptosis
Role of Short- and Long-Term Signaling Pathways
- Eva Hammar1,
- Géraldine Parnaud1,
- Domenico Bosco2,
- Nadja Perriraz1,
- Kathrin Maedler3,
- Marc Donath3,
- Dominique G. Rouiller1 and
- Philippe A. Halban1
- 1Department of Genetic Medicine and Development, University Medical Center, University Hospital, Geneva, Switzerland
- 2Cell Isolation and Transplantation Center, University Hospital, Geneva, Switzerland
- 3Division of Endocrinology and Diabetes, University Hospital, Zurich, Switzerland
- Address correspondence and reprint requests to Eva Hammar, Department of Genetic Medecine and Development, University Medical Center, 9th Floor, Rue Michel Servet 1, 1211 Geneva 4, Switzerland. E-mail: eva.hammar{at}medecine.unige.ch
Abstract
We have shown previously that culture of β-cells on matrix derived from 804G cells and rich in laminin-5 improves their function. The purpose of this study was to investigate whether this matrix protects β-cells against apoptosis and to elucidate signaling pathways involved. Matrix protected sorted rat β-cells against apoptosis under standard conditions (11.2 mmol/l glucose, 10% serum), after serum deprivation (1% serum), and in response to interleukin-1β (IL-1β; 2 ng/ml), compared with control (poly-l-lysine [pLL]). Caspase-8 activity was reduced in cells cultured on matrix, whereas focal adhesion kinase (FAK), protein kinase B (PKB, or Akt), and extracellular signal–regulated kinase (ERK) phosphorylation was augmented. Treatment (4 h) with an anti-β1 integrin antibody, with the ERK pathway inhibitor PD98059, and/or with the phosphatidylinositol 3-kinase inhibitor LY294002 augmented cell death on 804G matrix but not on pLL. In long-term assays (48 h), PD98059 but not LY294002 drastically augmented cell death on 804G matrix but did so to a lesser extent on pLL. The protein inhibitor of nuclear factor-κB (IκBα) was overexpressed in cells cultured 18 h on matrix with partial blockade by PD98059. In summary, this study provides evidence for activation of signaling pathways and gene expression by extracellular matrix leading to improved β-cell survival.
- ECM, extracellular matrix
- ELISA, enzyme-linked immunosorbent assay
- ERK, extracellular signal–regulated kinase
- FAK, focal adhesion kinase
- GAPDH, glyceraldehyde-3-phosphate dehydrogenase
- HRP, horseradish peroxidase
- IκBα, inhibitor of nuclear factor κB
- IL-1β, interleukin-1β
- MAP, mitogen-activated protein
- MEK1, MAP kinase/ERK kinase
- NF-κB, nuclear factor-κB
- PI, phosphatidylinositol
- PKB, protein kinase B
- pLL, poly-l-lysine
- TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling
Footnotes
-
- Accepted May 12, 2004.
- Received January 21, 2004.
- DIABETES











